Usefulness of markers of cell proliferation in the management of pituitary adenomas
- PMID: 9680493
Usefulness of markers of cell proliferation in the management of pituitary adenomas
Abstract
1. Pituitary adenomas are benign and slow-growing tumours whose clinical manifestations depend mainly on the secretory activity of the adenomatous cells. Except for prolactinomas, surgical removal of the tumour is the therapy of choice. 2. Despite extensive research on their clinical and pathophysiological aspects, few studies have explored the oncological characteristics of these rare lesions. Among these, the growth fraction of pituitary adenomas has been determined by different methods, of which the most useful are those performed in archival material. 3. The results reported in the literature show that adrenocorticotropic hormone-secreting tumours seem to be characterized by a higher proliferation index than the other types of pituitary adenomas, despite their usually small tumour size. 4. In small series of patients radiotherapy and medical treatment with dopaminergic drugs and octreotide were associated with a lower proliferation index than untreated tumours. Tumour size was not correlated with the growth fraction of the pituitary tumours, whereas invasiveness was correlated in most studies. 5. From a clinical point of view, however, the more promising utilization of the proliferation index seems to be in predicting the potential of recurrence of the tumour, thus allowing a more rational approach to follow-up and further treatment of patients with pituitary adenomas.
Similar articles
-
Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: relationship to tumour behaviour.Br J Cancer. 2000 Apr;82(8):1441-5. doi: 10.1054/bjoc.1999.1074. Br J Cancer. 2000. PMID: 10780524 Free PMC article.
-
Expression of cell proliferation markers in pituitary adenomas--correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha.Acta Neurochir (Wien). 2004 Aug;146(8):831-9. doi: 10.1007/s00701-004-0298-0. Epub 2004 Jun 14. Acta Neurochir (Wien). 2004. PMID: 15254805
-
Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study.Clin Endocrinol (Oxf). 2006 Oct;65(4):536-43. doi: 10.1111/j.1365-2265.2006.02630.x. Clin Endocrinol (Oxf). 2006. PMID: 16984249
-
Pituitary adenoma: a radiotherapeutic perspective.Am J Clin Oncol. 2010 Aug;33(4):408-19. doi: 10.1097/COC.0b013e31819d878d. Am J Clin Oncol. 2010. PMID: 19687730 Review.
-
The effect of growth hormone on pituitary tumour growth.Curr Opin Endocrinol Diabetes Obes. 2010 Aug;17(4):365-8. doi: 10.1097/MED.0b013e32833b4fa3. Curr Opin Endocrinol Diabetes Obes. 2010. PMID: 20498595 Review.
Cited by
-
Determination of the proliferation and apoptotic index in adrenocorticotropin-secreting pituitary tumors : comparison between micro- and macroadenomas.Am J Pathol. 2000 Jan;156(1):245-51. doi: 10.1016/S0002-9440(10)64725-6. Am J Pathol. 2000. PMID: 10623673 Free PMC article.
-
Determination of cell proliferation using Mcm2 antigen and evaluation of apoptosis and TGF-beta1 expression in GH-secreting or clinically nonfunctioning pituitary adenomas.Endocr Pathol. 2010 Mar;21(1):32-9. doi: 10.1007/s12022-010-9107-x. Endocr Pathol. 2010. PMID: 20174894
-
Expression of proliferation markers in human pituitary incidentalomas.Endocr Pathol. 2006 Fall;17(3):263-75. doi: 10.1385/ep:17:3:263. Endocr Pathol. 2006. PMID: 17308363
-
Effect of Dopamine Agonists on Lactotroph Adenomas of the Human Pituitary.Endocr Pathol. 2000 Winter;11(4):341-352. doi: 10.1385/ep:11:4:341. Endocr Pathol. 2000. PMID: 12114758
-
DNA-flow cytometry of 207 pituitary adenomas: ploidy, proliferation, and prognosis.J Endocrinol Invest. 2005 Oct;28(9):795-801. doi: 10.1007/BF03347568. J Endocrinol Invest. 2005. PMID: 16370557
MeSH terms
Substances
LinkOut - more resources
Medical